Leukemia
Dihydroorotate dehydrogenase inhibitors may increase chemotherapy effectiveness in AML
Acalabrutinib appears effective, safe for advanced CLL
Acalabrutinib appeared effective and safe compared with standard regimens for relapsed or refractory chronic lymphocytic leukemia, according to long-term study results presented at Society of Hematologic Oncology Annual Meeting.
Pediatric protocol confers favorable outcomes for adolescents, young adults with ALL
Global trial ‘aligned around a single mission’ of advancing pediatric leukemia treatments
A collaborative global master clinical trial by The Leukemia & Lymphoma Society, Children’s Oncology Group and NCI aims to meaningfully advance the development of targeted treatments for children with acute leukemia.
Tool appears to predict need for treatment in asymptomatic, early-stage CLL
A novel prognostic tool appeared to predict the need for treatment among patients with asymptomatic, early-stage, chronic lymphocytic leukemia, according to research published in Blood.
Azacitidine plus venetoclax effective, safe for certain patients with AML
The addition of azacitidine to venetoclax significantly improved response rates and OS among certain patients with acute myeloid leukemia, according to study results presented at the virtual European Hematology Association Annual Congress.
Children with Down syndrome, ALL at higher risk for poor outcomes
Children with Down syndrome and acute lymphoblastic leukemia continue to experience poorer outcomes than children with ALL who do not have Down syndrome, according to study results presented during the ASCO20 Virtual Scientific Program.
‘Chemo brain’: An imprecise term for a complex phenomenon
The various cognitive impairments collectively known as “chemo brain” can cause anxiety, frustration and difficulty with everyday tasks for cancer survivors.